Misdiagnosis is frequent in early motor neuron disease (MND), typically compressive radiculopathy, or in patients with restricted MND phenotype. In this retrospective, single tertiary centre study, we measured levels of neurofilament light (NfL) and phosphorylated neurofilament heavy (p-NfH) chain in cerebrospinal fluid (CSF) and of p-NfH in serum with commercially available ELISA kits and assessed their respective diagnostic performance as a marker of MND. The entire study population (n = 164) comprised 71 MND patients, 30 patients with compressive myelo- or radiculopathy, and 63 disease controls (DC). Among MND patients, we specified subgroups with only lower motoneuron involvement (MND-LMN, n = 15) and with confounding nerve roots or spinal cord compression (MND-C, n = 18), representing clinical diagnostic pitfalls. MND-LMN displayed significantly lower CSF NfL (p = 0.003) and p-NFH (p = 0.017), but not serum p-NfH (p = 0.347) levels compared to other MND patients (n = 56). The discriminative ability (area under the curve-AUC) of both CSF Nfs towards all MND patients was comparable to each other but significantly higher than that of p-NfH in serum (ps < 0.001). AUC of both CSF Nfs between MND-LMN and DC and also between MND-C and myelo-/radiculopathies were reduced, as compared to AUC between other MND and DC or myelo-/radiculopathies, respectively. Our results suggest that both Nfs in CSF represent a reliable diagnostic marker in a general MND population, fulfilling Awaji criteria. As for diagnostic pitfalls, and also for p-NfH in serum, their discriminative ability and, therefore, clinical utility appears to be limited.

Department of Immunology Charles University 2nd Faculty of Medicine and University Hospital Motol 5 Uvalu 84 150 06 Prague Czech Republic

Neuromuscular Centre Department of Neurology Charles University 2nd Faculty of Medicine and University Hospital Motol 5 Uvalu 84 150 06 Prague Czech Republic

See more in PubMed

Chiò A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82(7):740–746. https://doi.org/10.1136/jnnp.2010.235952 PubMed DOI

Bendotti C, Bonetto V, Pupillo E et al (2020) Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 21(7–8):485–495. https://doi.org/10.1080/21678421.2020.1779298 PubMed DOI

Cellura E, Spataro R, Taiello AC, La Bella V (2012) Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 114(6):550–554. https://doi.org/10.1016/j.clineuro.2011.11.026 PubMed DOI

Srinivasan J, Scala S, Jones HR, Saleh F, Russell JA (2006) Inappropriate surgeries resulting from misdiagnosis of early amyotrophic lateral sclerosis. Muscle Nerve 34(3):359–360. https://doi.org/10.1002/mus.20555 PubMed DOI

Pinto S, Swash M, de Carvalho M (2014) Does surgery accelerate progression of amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 85(6):643–646. https://doi.org/10.1136/jnnp-2013-305770 PubMed DOI

Sanderson AB, Arnold WD, Elsheikh B, Kissel JT (2015) The clinical spectrum of isolated peripheral motor dysfunction. Muscle Nerve 51(3):358–362. https://doi.org/10.1002/mus.24326 PubMed DOI PMC

Simon NG, Ayer G, Lomen-Hoerth C (2013) Is IVIg therapy warranted in progressive lower motor neuron syndromes without conduction block? Neurology 81(24):2116–2120. https://doi.org/10.1212/01.wnl.0000437301.28441.7e PubMed DOI PMC

Poesen K, Van Damme P (2019) Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 18(9):1167. https://doi.org/10.3389/fneur.2018.01167 DOI

Yuan A, Rao MV, Veeranna, Nixon RA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 9(4):a018309. https://doi.org/10.1101/cshperspect.a018309 (Published 2017 Apr 3) PubMed DOI PMC

Lobsiger CS, Cleveland DW (2009) Neurofilaments: organization and function in neurons. In: Squire LR (ed) Encyclopedia of neuroscience. Elsevier, Amsterdam, pp 433–436. https://doi.org/10.1016/B978-008045046-9.00728-2 DOI

Gaiottino J, Norgren N, Dobson R et al (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8(9):e75091. https://doi.org/10.1371/journal.pone.0075091 PubMed DOI PMC

Bridel C, van Wieringen WN, Zetterberg H et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76(9):1035–1048. https://doi.org/10.1001/jamaneurol.2019.1534 PubMed DOI PMC

Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A (2010) A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 220(1–2):114–119. https://doi.org/10.1016/j.jneuroim.2010.01.004 PubMed DOI

Kušnierová P, Zeman D, Hradílek P, Čábal M, Zapletalová O (2019) Neurofilament levels in patients with neurological diseases: a comparison of neurofilament light and heavy chain levels. J Clin Lab Anal 33(7):e22948. https://doi.org/10.1002/jcla.22948 PubMed DOI PMC

Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V (2018) CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol 265(3):510–521. https://doi.org/10.1007/s00415-017-8730-6 PubMed DOI

Ohya J, Chikuda H, Kato S, Hayakawa K, Oka H, Takeshita K, Tanaka S, Ogata T (2015) Elevated levels of phosphorylated neurofilament heavy subunit in the cerebrospinal fluid of patients with lumbar spinal stenosis: preliminary findings. Spine J 15(7):1587–1592. https://doi.org/10.1016/j.spinee.2015.03.013 PubMed DOI

Takahashi H, Aoki Y, Nakajima A et al (2018) Axonal damage is remarkable in patients with acutely worsening symptoms of compression myelopathy: biomarkers in cerebrospinal fluid samples. Eur Spine J 27(8):1824–1830. https://doi.org/10.1007/s00586-018-5549-5 PubMed DOI

Poesen K, De Schaepdryver M, Stubendorff B et al (2017) Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88(24):2302–2309. https://doi.org/10.1212/WNL.0000000000004029 PubMed DOI

De Schaepdryver M, Jeromin A, Gille B, Claeys KG, Herbst V, Brix B, Van Damme P, Poesen K (2018) Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89(4):367–373. https://doi.org/10.1136/jnnp-2017-316605 PubMed DOI

Steinacker P, Feneberg E, Weishaupt J et al (2016) Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12–20. https://doi.org/10.1136/jnnp-2015-311387 PubMed DOI

Gaiani A, Martinelli I, Bello L et al (2017) Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 74(5):525–532. https://doi.org/10.1001/jamaneurol.2016.5398 PubMed DOI PMC

Falzone YM, Domi T, Agosta F et al (2020) Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J Neurol 267(8):2272–2280. https://doi.org/10.1007/s00415-020-09838-9 PubMed DOI PMC

Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J, WFN Research Group On ALS/MND (2015) A revision of the El Escorial criteria 2015. Amyotroph Lateral Scler Frontotemporal Degener. 16(56):291–292. https://doi.org/10.3109/21678421.2015.1049183 PubMed DOI

Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Shinoda K, Sugino M, Hanafusa T (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66(2):265–267. https://doi.org/10.1212/01.wnl.0000194316.91908.8a PubMed DOI

Lee SH, Kim KT, Suk KS, Lee JH, Shin JH, So DH, Kwack YH (2010) Asymptomatic cervical cord compression in lumbar spinal stenosis patients: a whole spine magnetic resonance imaging study. Spine (Phila Pa). 35(23):2057–2063. https://doi.org/10.1097/BRS.0b013e3181f4588a DOI

Schönström N, Willén J (2001) Imaging lumbar spinal stenosis. Radiol Clin N Am 39(1):31–53. https://doi.org/10.1016/s0033-8389(05)70262-1 PubMed DOI

Halbgebauer S, Steinacker P, Verde F, Weishaupt J, Oeckl P, von Arnim C, Dorst J, Feneberg E, Mayer B, Rosenbohm A, Silani V, Ludolph AC, Otto M (2022) Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry 93(1):68–74. https://doi.org/10.1136/jnnp-2021-327129 PubMed DOI

Lu CH, Petzold A, Topping J et al (2015) Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry 86(5):565–573. https://doi.org/10.1136/jnnp-2014-307672 PubMed DOI

Wilke C, Pujol-Calderón F, Barro C et al (2019) Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clin Chem Lab Med 57(10):1556–1564. https://doi.org/10.1515/cclm-2019-0015 PubMed DOI

Schreiber S, Spotorno N, Schreiber F et al (2018) Significance of CSF NfL and tau in ALS. J Neurol 265(11):2633–2645. https://doi.org/10.1007/s00415-018-9043-0 PubMed DOI

Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, Turner MR (2015) CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2(7):748–755. https://doi.org/10.1002/acn3.212 PubMed DOI PMC